About NOXXON
NOXXON’s oncology-focused pipeline acts on the cancer immunity cycle by breaking the tumor protection barrier, blocking tumor repair and exposing hidden tumor cells. Through neutralizing chemokines in the tumor micro-environment, NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact. Building on extensive clinical experience and safety data, lead program NOX-A12 will deliver top-line data from a combination trial with the immuno-oncology checkpoint inhibitor, Keytruda®, in metastatic colorectal and pancreatic cancer patients in 2018.
| • Download the initiation report on NOXXON by Aurgalys |
| ➥ See latest updates from Aurgalys here |
Press ReleaseBerlin, Germany
2018, September 19 6:00 p.m. NOXXON announces listing of convertible bonds and additional investment 2018, September 19 8:00 a.m. NOXXON to present clinical trial data at Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference 'Translating Science into Survival' 2018, September 03 8:00 a.m. NOXXON announces completion of patient recruitment in ongoing NOX-A12 pancreatic and colorectal cancer trial |
EventsDownload PresentationAram Mangasarian, Ewelina Staniuk Aram Mangasarian, Jarl Ulf Jungnelius Aram Mangasarian, Jarl Ulf Jungnelius |